On November 2, 2026, the U.S. Food and Drug Administration (FDA) published a proposed rule that would revise nutrient specifications and labeling requirements for infant formula as part of Operation Stork Speed. The proposal would change the permitted levels of four nutrients and require labeling changes even for products that do not need reformulation. Comments are due by March 2, 2027.
FDA's existing regulations establish specifications for 30 nutrients in infant formula, with a minimum amount for each and a maximum amount for some. Through Operation Stork Speed, FDA is reviewing whether those requirements reflect current scientific evidence about infants' nutritional needs and the risks of excessive nutrient intake. As we previously wrote, FDA began this review with a May 2025 request for information.
FDA is conducting the review in stages. In the November proposal, the agency evaluated the evidence for eight of the 30 required nutrients and determined that the requirements for four should change, while those for the other four should remain the same. FDA plans to address the remaining nutrients in subsequent proposed rules and then issue a single final rule covering all changes resulting from the review.
Proposed Nutrient and Labeling Changes
FDA proposes changing the minimum and/or maximum amounts of iodine, vitamin A, vitamin D, and manganese, as shown below. All amounts are measured per 100 kilocalories of formula. For vitamin A, the proposal would replace international units (IU) with micrograms of retinol activity equivalents (RAE), a measure of vitamin A activity. Vitamin D would be expressed in micrograms rather than IU.
Nutrient |
Current requirements |
Proposed requirements |
|---|---|---|
Iodine |
5-75 micrograms |
15-50 micrograms |
Vitamin A |
250-750 IU |
70-120 micrograms RAE |
Vitamin D |
40-100 IU |
2-3 micrograms |
Manganese |
Minimum of 5 micrograms; |
1-50 micrograms |
For the other four nutrients evaluated in this proposal—chloride, selenium, potassium, and sodium—FDA concluded that the existing requirements remain appropriate and proposes no changes.
Importantly, the proposal would also change which sources count toward the vitamin A requirements. Currently, manufacturers may rely on preformed vitamin A (retinol and retinyl esters) or beta-carotene, which the body converts to vitamin A. Under the proposal, retinol and retinyl esters would continue to count toward the required minimum and maximum. Beta-carotene could still be used in infant formula but would no longer count toward those requirements.
The new units of measurement would also apply to labeling. Labels would have to declare vitamin A in micrograms RAE and vitamin D in micrograms, rather than IU. Manufacturers could continue to provide IU equivalents voluntarily in parentheses immediately following those declarations. Accordingly, even products whose nutrient levels already fall within the proposed ranges would need updated labels.
Additional Nutrient Requirements Under Consideration
In addition to the changes described above, FDA is seeking comments on other nutrients to inform later proposals. The agency asks whether three fatty acids—docosahexaenoic acid (DHA), arachidonic acid (ARA), and alpha-linolenic acid (ALA)—should become required nutrients, and what amounts and ratios would be appropriate. FDA also asks whether to require L-carnitine, a compound involved in energy metabolism.
Separately, FDA seeks input on whether existing iron requirements should change and whether they should differ based on infants' age or other risk factors.
When Would Manufacturers Need to Comply?
FDA proposes that the single final rule covering the full nutrient review take effect 60 days after publication. Manufacturers would then have three years from that effective date to comply.
What Should Infant Formula Manufacturers Do?
Companies should consider submitting comments, individually or through industry groups, supported by relevant scientific, technical, and operational data. To inform their comments, companies should evaluate whether the changes FDA proposed are feasible and what they would cost to implement.
If you are interested in submitting comments or have any questions about the proposed rule, Venable's FDA team is ready and able to assist.